- Home
- SUPV vs DBVT Comparison
SUPV vs DBVT Comparison
Compare SUPV & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SUPV | DBVT |
|---|---|---|
| Founded | 1887 | 2002 |
| Country | Argentina | France |
| Employees | N/A | 90 |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.9M | 948.8M |
| IPO Year | 2015 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SUPV | DBVT |
|---|---|---|
| Price | $9.79 | $17.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $13.00 | ★ $32.04 |
| AVG Volume (30 Days) | ★ 819.0K | 306.8K |
| Earning Date | 05-26-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,636,000.00 |
| Revenue This Year | $86.20 | $35.04 |
| Revenue Next Year | $25.12 | $2,360.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 35.77 |
| 52 Week Low | $4.54 | $8.51 |
| 52 Week High | $13.55 | $26.19 |
Technical Indicators
Market Signals| Indicator | SUPV | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 49.85 | 51.29 |
| Support Level | $9.27 | $16.05 |
| Resistance Level | $10.12 | $17.36 |
| Average True Range (ATR) | 0.64 | 1.08 |
| MACD | -0.11 | 0.14 |
| Stochastic Oscillator | 25.54 | 58.10 |
Price Performance
Historical ComparisonAbout SUPV Grupo Supervielle S.A. each Representing five Class B shares
Grupo Supervielle SA offers financial products & services. The company's segments include Personal and Business Banking, Corporate Banking, Bank Treasury, Consumer Finance, Insurance, and Asset Management and other services. The company provides services to individuals, small businesses, middle-market companies, and large corporates in Argentina. The company also offers mutual fund services.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.